-+ 0.00%
-+ 0.00%
-+ 0.00%

Monopar Phase 3 Data Show Persistent Disease Burden in Treated Wilson Disease Patients

PUBT·11/09/2026 13:02:28
Listen to the news
Monopar Phase 3 Data Show Persistent Disease Burden in Treated Wilson Disease Patients
  • Monopar Therapeutics presented Phase 3 FoCus baseline findings and ALXN1840 safety data at AASLD’s The Liver Meeting 2026, held Nov. 5-9.
  • Baseline findings showed substantial residual Wilson disease burden despite long-term standard treatment, highlighting persistent unmet medical needs.
  • Investigational therapy ALXN1840 showed no molybdenum toxicity, with uric acid remaining normal over six years, supporting its long-term safety profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090800PRIMZONEFULLFEED9872970) on November 09, 2026, and is solely responsible for the information contained therein.